Results 81 to 90 of about 2,979 (146)

Role of ATP citrate lyase and its complementary partner on fatty acid synthesis in gastric cancer

Scientific Reports
ATP citrate lyase (ACLY) and acyl-CoA short-chain synthetases 2 (ACSS2) are key enzymes in lipid metabolism. We explored the role of ACLY in gastric cancer (GC) and the effect of ACLY and ACSS2 compensation on GC growth.
Chunlei Li, Wenxuan Liu, Youzhao Liu, Weixing Wang, Wenhong Deng   +4 more
doaj   +1 more source

ACSS2 mediates an epigenetic pathway to regulate β-cell adaptation during gestation in mice

Nature Communications
Maternal pancreatic β-cells undergo adaptive changes to meet the metabolic demands of pregnancy, and disruptions in this adaptation can lead to gestational diabetes mellitus. However, the mechanisms governing this adaptation remain largely unexplored. Using single-cell transcriptome combined with genetic analyses, we identified a precise process of β ...
Yu Zhang, Shuang He, Xi Wang, Xin Wang, Mao-Yang He, Xin-Xin Yu, Cheng-Ran Xu   +6 more
openaire   +3 more sources

Inhibition of ACSS2 for Treatment of Cancer and Neuropsychiatric Diseases [PDF]

ACS Medicinal Chemistry Letters, 2019
openaire   +2 more sources

Amide-Substituted Condensed Pyridine Derivatives as ACSS2 Inhibitors for Treating Cancer [PDF]

ACS Medicinal Chemistry Letters, 2021
openaire   +2 more sources

HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma

The Journal of Clinical Investigation
Clear cell renal cell carcinoma (ccRCC) is an aggressive cancer driven by VHL loss and aberrant HIF-2α signaling. Identifying means to regulate HIF-2α thus has potential therapeutic benefit.
Zachary A. Bacigalupa, Emily N. Arner, Logan M. Vlach, Melissa M. Wolf, Whitney A. Brown, Evan S. Krystofiak, Xiang Ye, Rachel A. Hongo, Madelyn Landis, Edith K. Amason, Kathryn E. Beckermann, W. Kimryn Rathmell, Jeffrey C. Rathmell   +12 more
doaj   +1 more source

Dual inhibition of hepatic ACLY and ACSS2: A synergistic approach to combat NAFLD through lipogenesis reduction and mitochondrial enhancement

Pharmacological Research
Inhibiting de novo lipogenesis (DNL) in hepatocytes is a promising strategy for treating metabolic fatty liver diseases. ACLY, a key enzyme in the DNL pathway, has become a therapeutic target for non-alcoholic fatty liver disease (NAFLD).
Mengdi Zhang, Jinliang Ji, Yuanyuan Lei, Fujian Qin, Yitong Tao, Ning Li, Jinlei Bian, Zhiyu Li, Maode Lai, Zhixia Qiu   +9 more
doaj   +1 more source

ACSS2 gene variants determine kidney disease risk by controlling de novo lipogenesis in kidney tubules

The Journal of Clinical Investigation
Worldwide, over 800 million people are affected by kidney disease, yet its pathogenesis remains elusive, hindering the development of novel therapeutics.
Dhanunjay Mukhi, Lingzhi Li, Hongbo Liu, Tomohito Doke, Lakshmi P. Kolligundla, Eunji Ha, Konstantin Kloetzer, Amin Abedini, Sarmistha Mukherjee, Junnan Wu, Poonam Dhillon, Hailong Hu, Dongyin Guan, Katsuhiko Funai, Kahealani Uehara, Paul M. Titchenell, Joseph A. Baur, Kathryn E. Wellen, Katalin Susztak   +18 more
doaj   +1 more source

Chuangling Ye mitigates diabetic foot ulcer through suppressing keratinocyte ferroptosis via inhibiting ACSS2/ACSL4 axis. [PDF]

Chin Med
Feng X, Yi N, Zhang C, Tang L, Yin X, Zhao Y, Zhu T, Zhu J, Feng Q, Chen W, Xia Y, Ma C.   +11 more
europepmc   +1 more source

Polystyrene nanoparticles promote endometrial cancer development through the ACSS2-mediated reprogramming of arachidonic acid metabolism. [PDF]

Cell Death Discov
Huang X, Xu L, Wang J, Cheng J, Yuan J, Liu X, Larionova I, Kzhyshkowska J, Chen S, Zhao Y.   +9 more
europepmc   +1 more source

Ablation of ACSS2 drives alteration to cardiac and hepatic proteomic landscapes in a tissue- and sex-specific manner. [PDF]

J Proteomics
Winters AM, Wohlfahrt J, Wolf T, Sarkar A, Patel SJ, Guergues J, Burkhardt BR, Stevens SM.   +7 more
europepmc   +1 more source